Bone-Pain Palliation: Sr-89, Sm-153, and Ra-223

Bone-seeking radiopharmaceuticals deliver radiation directly to osteoblastic skeletal metastases, and the choice among strontium-89, samarium-153, and radium-223 is fundamentally a physics decision. The beta emitters strontium-89 chloride and samarium-153 EDTMP palliate metastatic bone pain; the alpha emitter radium-223 dichloride both palliates and prolongs survival in metastatic castration-resistant prostate cancer. Their emission type, energy, half-life, tissue range, and red-marrow dose explain the differences in efficacy, toxicity, and radiation safety. ¹²³

For a nuclear medicine program, these agents sit at the intersection of oncology, internal dosimetry, and radioactive-material regulation. Each requires a written directive, an authorized user, a defensible estimate of the dose to the organ at risk, and a patient-release and contamination-control plan. This guide compares the three agents on the physics that matters, works through a red-marrow dose estimate, and lays out the regulatory and safety framework. DRPS supports nuclear medicine and theranostics programs across Florida, Maryland, Virginia, Washington DC, California, Nevada, Pennsylvania, New York, New Jersey, and Delaware with PET/CT and nuclear medicine physics and radioactive material license support.

Introduction

Skeletal metastases are common in advanced prostate, breast, and lung cancer and are a major source of pain, reduced quality of life, and skeletal complications. Bone-seeking radiopharmaceuticals exploit the increased osteoblastic activity around metastases: calcium-mimetic or bone-avid molecules concentrate at sites of bone turnover, where their emitted radiation deposits dose over a short range and treats multiple lesions in a single systemic administration. ²³

Three agents are approved in the United States for this purpose. Strontium-89 chloride and samarium-153 EDTMP are beta-emitting agents that have been used for decades primarily to palliate pain. Radium-223 dichloride is an alpha-emitting agent that changed the paradigm: in the phase 3 ALSYMPCA trial it not only reduced symptomatic skeletal events but significantly prolonged overall survival, making it the first bone-targeted radiopharmaceutical with a proven disease-modifying benefit. ⁴⁵⁹

The distinction between beta and alpha emission is not academic. It determines how far the radiation travels, how much dose reaches the red marrow, how much myelosuppression to expect, and what contamination controls the radiation safety program must emphasize. A medical physicist's job is to make those physics explicit so the clinical team can dose safely and defensibly.

Topic Explanation

How bone-seeking radiopharmaceuticals work

These agents localize to regions of active bone mineralization surrounding osteoblastic metastases and deliver a short-range radiation dose to the adjacent tumor and bone. Strontium-89 is a calcium analog that is incorporated into hydroxyapatite at sites of bone turnover. Samarium-153 is chelated to EDTMP, a phosphonate that binds to hydroxyapatite much like the diphosphonates used in bone scintigraphy. Radium-223 is a calcium-mimetic alkaline-earth element that also deposits at sites of active mineralization. In all three, uptake is highest where osteoblastic activity is greatest — precisely at the metastatic lesions that cause pain. ²³⁶

Because uptake follows bone turnover, the same osteoblastic avidity seen on a Tc-99m MDP bone scan predicts which patients are good candidates: a positive bone scan showing osteoblastic disease is a prerequisite. For the imaging counterpart, see our overview of Tc-99m MDP bone scintigraphy.

The three agents at a glance

Property	Strontium-89 chloride	Samarium-153 EDTMP	Radium-223 dichloride
Emission	Beta (β⁻)	Beta (β⁻) + 103 keV gamma	Alpha (α) + minor photons
Beta max energy	~1.46 MeV	0.81 / 0.71 / 0.64 MeV	— (alpha ~5–7 MeV)
Physical half-life	~50.5 days	~46.3 hours (1.93 days)	~11.4 days
Approx. max range in tissue	~7 mm	~3 mm	under 0.1 mm
Imageable photon	Bremsstrahlung only	Yes (103 keV)	Limited photons
Typical administered activity	148 MBq (4 mCi) fixed	37 MBq/kg (1.0 mCi/kg)	55 kBq/kg, monthly × 6
Primary clinical role	Pain palliation	Pain palliation	Palliation + survival benefit
Marrow dose profile	Higher	Higher	Lower (marrow-sparing)

Values are representative starting points confirmed against the FDA prescribing information and the SNMMI/EANM practice guideline; a facility must verify the current label, calibration, and dosing for the specific product in use. ¹⁷¹⁰¹³

Key Technical Principles

Alpha versus beta: range and linear energy transfer

The central physics distinction is between the short-range, high-LET alpha particle of radium-223 and the longer-range, low-LET beta particles of strontium-89 and samarium-153.

Alpha particles from radium-223 and its decay chain travel less than about 100 micrometers in tissue — only a few cell diameters — and deposit energy at high linear energy transfer (LET). This concentrates dose within the bone metastasis and the immediately adjacent bone surface while sparing much of the red marrow a short distance away. The high LET also produces dense, difficult-to-repair DNA damage, contributing to the disease-modifying effect. ⁴⁵

Beta particles have a continuous energy spectrum and travel millimeter-scale distances: strontium-89's 1.46 MeV maximum beta reaches on the order of 7 mm at maximum energy, and samarium-153's softer betas reach a few millimeters. That longer range treats a larger volume around each lesion but also delivers more dose to the red marrow, which is the organ at risk and the source of the dose-limiting myelosuppression. ²⁶

The practical consequence is a different therapeutic-index profile. Alpha therapy with radium-223 delivers relatively marrow-sparing, highly localized dose; beta therapy palliates effectively but at the cost of greater, though generally reversible, marrow toxicity. ²⁶

Estimating red-marrow absorbed dose

Red marrow is the organ at risk, so a marrow-dose estimate anchors safe dosing. In the simplest formulation, the administered activity is set by patient weight, and the marrow dose follows from a marrow dose coefficient. For samarium-153 EDTMP administered at $a_{wt} = 37 MBq/kg$ to a 70 kg patient, the administered activity is:

A = a_{wt} \cdot m = 37 \frac{MBq}{kg} \times 70 kg = 2590 MBq = 2.59 GBq

Applying a published red-marrow dose coefficient of approximately $d_{rm} = 0.8 Gy/GBq$ for Sm-153 EDTMP:

D_{rm} = A \cdot d_{rm} = 2.59 GBq \times 0.8 \frac{Gy}{GBq} \approx 2.1 Gy

This estimate matches individualized dosimetry studies that report a median red-marrow dose near 2.1 Gy at this weight-based activity, with substantial patient-to-patient variability driven by differences in skeletal uptake and urinary clearance — one reason patient-specific pharmacokinetics improve on a fixed weight-based dose. ⁷ Historically, reversible myelotoxicity was frequently observed once red-marrow doses reached about 2.7 Gy (270 cGy), which is why marrow dose and blood counts are watched closely. ⁶ The formal framework for these calculations is the MIRD schema; see our primer on the MIRD schema for internal dosimetry.

Physical decay and the radium-223 dosing schedule

Radium-223 is administered as six injections at four-week intervals. Its 11.4-day physical half-life means each administered activity decays substantially before the next dose. Using the decay law with $λ = ln 2/ T_{1/2}$ , the fraction of an injected activity remaining after one 28-day interval is:

\frac{A ( t )}{A _{0}} = e^{- λ t} = e^{- \frac{l n 2}{11.4} \times 28} = e^{- 1.70} \approx 0.18

so only about 18 percent of a given injection's radium-223 remains at the time of the next injection, and the alpha-emitting decay chain deposits most of its energy within days of each administration. This short effective persistence, combined with the sub-100-micrometer alpha range, is why radium-223 produces low external dose rates and limited whole-body exposure despite its potent local effect. ¹⁴

Clinical Impact

Pain palliation across all three agents

All three agents provide meaningful pain relief for a majority of appropriately selected patients with osteoblastic metastases. Early samarium-153 work reported pain relief within 14 days in about 79 percent of evaluable patients, with response durations of several weeks and the option of retreatment. ⁶ Strontium-89 and samarium-153 have similar palliative efficacy in randomized comparisons, with response rates commonly cited in the 60 to 80 percent range, though neither beta emitter demonstrated an overall survival benefit in the pivotal trials. ²³

Radium-223 and survival

Radium-223 is distinguished by its survival benefit. In the ALSYMPCA phase 3 trial of men with metastatic castration-resistant prostate cancer and symptomatic bone metastases, radium-223 significantly prolonged median overall survival compared with placebo (14.9 versus 11.3 months; hazard ratio 0.70) and delayed the time to the first symptomatic skeletal event, with low rates of myelosuppression. ⁹ These results moved radium-223 from a purely palliative role to a disease-modifying therapy and made it the dominant bone-targeted agent for this population. For a focused treatment discussion, see our article on radium-223 dichloride therapy for prostate cancer. ⁵

Toxicity and patient selection

Myelosuppression — chiefly reversible thrombocytopenia and leukopenia — is the dose-limiting toxicity across the class, and it is the direct clinical expression of red-marrow dose. It is more pronounced with the beta emitters and least with radium-223. Patients need adequate baseline marrow reserve, a positive osteoblastic bone scan, and no untreated impending pathologic fracture or cord compression. Blood counts are monitored before and after each administration. The physics theme recurs: the agent that concentrates dose most tightly in bone (radium-223) is also the best tolerated by the marrow. ²⁵⁶

Practical Optimization Tips

Confirm osteoblastic disease first. A positive Tc-99m MDP or F-18 NaF bone scan showing osteoblastic uptake is the entry criterion; purely lytic or visceral-dominant disease is not the target.
Verify current product availability. Samarium-153 EDTMP has faced supply interruptions; confirm the product and its calibration before scheduling. ¹
Estimate marrow dose and review counts. Anchor dosing to a marrow-dose estimate and to baseline and interval blood counts, not to activity alone. ⁶⁷
Plan contamination control before administration. For the beta emitters excreted in urine, brief the patient on toilet hygiene and manage potentially contaminated linens and dressings.
Complete the six-cycle radium-223 course when tolerated. Survival benefit in ALSYMPCA was tied to the full regimen; response should not be judged by PSA, which is not a marker of radium-223 benefit. ⁵⁹
Coordinate with other therapies. Sequencing with chemotherapy, hormonal agents, and external-beam radiotherapy to focal painful sites should be planned with the oncology team. ²⁸

Common pitfalls to avoid

Treating the wrong disease pattern. Lytic-only or visceral-dominant metastases are not appropriate targets.
Ignoring marrow reserve. Inadequate baseline counts predict problematic myelosuppression.
Assuming all three agents behave alike. They differ in range, marrow dose, and — for radium-223 — survival benefit.
Underplaying contamination control. Low external dose does not mean no radiation-safety obligation; urinary and body-fluid contamination still require handling instructions.

Regulatory Considerations

Strontium-89, samarium-153, and radium-223 are unsealed byproduct material, so their medical use is governed by NRC or Agreement State regulations under the framework of 10 CFR Part 35. Administration requires an authorized user, a written directive signed before administration, and compliance with the facility's radioactive material license and the dosimetry, survey, and recordkeeping requirements of Parts 35 and 20. ¹⁰¹¹

Key regulatory anchors:

10 CFR Part 35 — Medical Use of Byproduct Material. Governs authorized users, written directives, dosage determination, and the safety procedures for unsealed therapeutic radiopharmaceuticals. ¹⁰
10 CFR Part 20 — Standards for Protection Against Radiation. Sets occupational and public dose limits and the ALARA framework that shape contamination control and patient-release decisions. ¹¹
NRC Regulatory Guide 8.39 — Release of Patients Administered Radioactive Material. Because external dose rates from these outpatient therapies are low, patients are generally released under 10 CFR 35.75 with written instructions; the guidance frames the dose-based release criteria and the instructions to give the patient and caregivers. ¹²
SNMMI Procedure Standard / EANM Practice Guideline for Palliative Nuclear Medicine Therapies of Bone Metastases. The current professional standard for patient selection, administration, and follow-up across strontium-89, samarium-153, and radium-223. ¹

Agreement States administer their own equivalent programs. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license medical use under their own radiation-control rules, while Washington DC and Delaware are regulated directly by the NRC. A facility must verify which authority issues its license and which written-directive, survey, and release requirements apply. For the caregiver side of release, see our guide to caregiver and family dose after radiopharmaceutical therapy.

From a radiation-safety standpoint, the emphasis differs by agent. The beta emitters are excreted substantially in urine, so contamination control of urine, blood, and soiled materials dominates the days after treatment. Radium-223, an alpha emitter, produces very low external exposure but still warrants standard body-fluid precautions and waste handling consistent with its decay chain. Programs starting these therapies should align dosing, dosimetry, written directives, waste handling, and release instructions with radioactive material license support and radiation safety officer guidance. ¹⁰¹¹¹²

Frequently Asked Questions (FAQs)

What radiopharmaceuticals are used for bone-pain palliation?

The three agents approved in the United States for painful skeletal metastases are strontium-89 chloride (a beta emitter), samarium-153 lexidronam or Sm-153 EDTMP (a beta emitter with an imageable gamma), and radium-223 dichloride (an alpha emitter). Radium-223 is unique in also prolonging overall survival in metastatic castration-resistant prostate cancer.

How is radium-223 different from strontium-89 and samarium-153?

Radium-223 emits alpha particles, which have a very short range in tissue (less than about 100 micrometers) and high linear energy transfer, concentrating dose in the bone metastasis while relatively sparing the marrow. Strontium-89 and samarium-153 emit beta particles with millimeter-scale range, delivering more dose to adjacent red marrow. Radium-223 also extends survival, whereas the beta emitters primarily palliate pain.

Do bone-pain palliation agents require a written directive?

Yes. Under 10 CFR Part 35, these unsealed byproduct therapies require a written directive signed by an authorized user before administration, and administration must be performed by or under the supervision of an authorized user in accordance with the facility's radioactive material license.

What is the main side effect of bone-seeking radiopharmaceuticals?

Myelosuppression, primarily reversible reductions in platelets and white cells, is the dose-limiting toxicity. It is more pronounced with the beta emitters strontium-89 and samarium-153, which deliver more dose to red marrow, and less pronounced with radium-223, whose short-range alpha emission spares much of the marrow.

Can patients be released after bone-pain palliation therapy?

Generally yes. External dose rates from these outpatient therapies are low, so patients are usually released under 10 CFR 35.75 with instructions consistent with NRC Regulatory Guide 8.39. The main radiation-safety emphasis is contamination control of urine and body fluids in the days after treatment, especially for the beta emitters excreted in urine.

Why does the medical physicist estimate red marrow dose?

Red marrow is the organ at risk for myelotoxicity. Estimating the absorbed dose to red marrow — from the administered activity, the agent's marrow dose coefficient, and patient-specific pharmacokinetics where available — supports safe dosing, patient selection, and interpretation of blood-count changes after therapy.

Is samarium-153 still available?

Availability has been limited. The originally marketed Sm-153 EDTMP product (Quadramet) has faced supply interruptions in the United States, and in current practice radium-223 has become the dominant bone-targeted agent for metastatic castration-resistant prostate cancer. A facility should confirm current product availability before planning a treatment.

Key Takeaways

Three agents, two physics families. Strontium-89 and samarium-153 are beta emitters; radium-223 is an alpha emitter — and that distinction drives everything downstream.
Range sets marrow dose. Millimeter-scale beta range deposits more dose in red marrow; sub-100-micrometer alpha range spares it.
Radium-223 is disease-modifying. ALSYMPCA showed a median overall survival benefit (14.9 vs 11.3 months, HR 0.70), not just palliation. ⁹
Marrow is the organ at risk. A red-marrow dose estimate (about 2.1 Gy for weight-based Sm-153 EDTMP in the worked example) anchors safe dosing. ⁷
Written directive and release plan are mandatory. These are unsealed byproduct therapies under 10 CFR Part 35 with patient release under 35.75 and Reg Guide 8.39. ¹⁰¹²
Contamination control fits the emitter. Urine and body-fluid precautions matter most for the urinary-excreted beta emitters.

Conclusion

Bone-pain palliation with radiopharmaceuticals is a clear example of physics driving clinical practice. The range and LET of the emitted radiation determine how much dose reaches the tumor versus the marrow, which in turn shapes efficacy, toxicity, and the survival benefit that sets radium-223 apart. A strong program treats each agent on its own terms: confirm osteoblastic disease, estimate the dose to the organ at risk, complete the written directive and dosimetry, plan contamination control and release, and document the whole chain. Handled that way, these therapies deliver real relief — and, for radium-223, extended survival — within a defensible radiation-safety and regulatory framework.

How DRPS Can Help

Diagnostic Radiation Physics Services supports nuclear medicine and theranostics programs delivering bone-targeted and other unsealed radiopharmaceutical therapies. Our board-certified medical physicists assist with internal dosimetry, written-directive and dosage-determination procedures, radiation-safety and contamination-control programs, patient-release calculations, and license support through PET/CT and nuclear medicine physics, radioactive material license support, and radiation safety officer services.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

A strong therapy program pairs clinical benefit with documented dosimetry and radiation safety — the two are not in tension.

Related Resources

References

Society of Nuclear Medicine and Molecular Imaging and European Association of Nuclear Medicine. SNMMI Procedure Standard / EANM Practice Guideline for Palliative Nuclear Medicine Therapies of Bone Metastases. snmmi.org
Murray I, Du Y. Systemic Radiotherapy of Bone Metastases With Radionuclides. Clinical Oncology. 2021;33(2):98-105. doi:10.1016/j.clon.2020.11.028. PubMed
Rubini G, Nicoletti A, Rubini D, Asabella AN. Radiometabolic treatment of bone-metastasizing cancer: from 186rhenium to 223radium. Cancer Biotherapy and Radiopharmaceuticals. 2014;29(1):1-11. doi:10.1089/cbr.2013.1549. PubMed
Brady D, Parker CC, O'Sullivan JM. Bone-targeting radiopharmaceuticals including radium-223. The Cancer Journal. 2013;19(1):71-78. doi:10.1097/PPO.0b013e318282479b. PubMed
Florimonte L, Dellavedova L, Maffioli LS. Radium-223 dichloride in clinical practice: a review. European Journal of Nuclear Medicine and Molecular Imaging. 2016;43(10):1896-1909. doi:10.1007/s00259-016-3386-5. PubMed
Turner JH, Martindale AA, Sorby P, et al. Samarium-153 EDTMP therapy of disseminated skeletal metastasis. European Journal of Nuclear Medicine. 1989;15(12):784-795. doi:10.1007/BF00255498. PubMed
Vigna L, Matheoud R, Ridone S, et al. Characterization of the [153Sm]Sm-EDTMP pharmacokinetics and estimation of radiation absorbed dose on an individual basis. Physica Medica. 2011;27(3):144-152. doi:10.1016/j.ejmp.2010.08.001. PubMed
Nilsson S. Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer. Current Oncology Reports. 2016;18(2):14. doi:10.1007/s11912-015-0495-4. PubMed
Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. New England Journal of Medicine. 2013;369(3):213-223. doi:10.1056/NEJMoa1213755. PubMed
U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. ecfr.gov
U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. ecfr.gov
U.S. Nuclear Regulatory Commission. Regulatory Guide 8.39: Release of Patients Administered Radioactive Material. nrc.gov
U.S. Food and Drug Administration. Xofigo (radium Ra 223 dichloride) prescribing information. accessdata.fda.gov